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Abstract The mechanism of action of protein-bound
polysaccharide K (PSK; KRESTIN
) involves the fol-
lowing actions: (1) recovery from immunosuppression
induced by humoral factors such as transforming growth
factor (TGF)-b or as a result of surgery and chemotherapy;
(2) activation of antitumor immune responses including
maturation of dendritic cells, correction of Th1/Th2
imbalance, and promotion of interleukin-15 production by
monocytes; and (3) enhancement of the antitumor effect of
chemotherapy by induction of apoptosis and inhibition of
metastasis through direct actions on tumor cells. The
clinical effectiveness of PSK has been demonstrated for
various cancers. In patients with gastric or colorectal can-
cer, combined use of PSK with postoperative adjuvant
chemotherapy prolongs survival, and this effect has been
conﬁrmed in multiple meta-analyses. For small-cell lung
carcinoma, PSK in conjunction with chemotherapy pro-
longs the remission period. In addition, PSK has been
shown to be effective against various other cancers, reduce
the adverse effects of chemotherapy, and improve quality
of life. Future studies should examine the effects of PSK
under different host immune conditions and tumor
properties, elucidate the mechanism of action exhibited in
each situation, and identify biomarkers.
Keywords PSK  Biological mechanism  Gastric
cancer  Colorectal cancer  Biomarker
Introduction
Whether humanimmunity is effective againstcancer, which
originates from mutation of the host’s normal cells, has long
been a subject of skepticism. In 1991, van der Bruggen et al.
[1] identiﬁed the tumor antigen in human melanoma that is
recognized by cytotoxic T lymphocytes (CTLs) and proved
at the molecular level that host immunity acts also against
cancer. Thereafter, immunotherapy was developed mainly
along the lines of vaccine therapy and cell therapy, with the
aim of boosting speciﬁc immunity [2]. Research began to
show that antigen-nonspeciﬁc innate immunity and antigen-
speciﬁc acquired immunity are closely associated via the
dendritic cells (DCs) that possess the important function of
antigen presentation [3]. Also, antigen-presenting cells
(APCs), including DCs, are known to be activated by rec-
ognizing various foreign pathogens via the Toll-like
receptors (TLRs) [4]. These developments indicate that
activation of nonspeciﬁc immunity plays certain roles in
augmenting antitumor immunity. However, the antitumor
effect of biological response modiﬁers (BRMs) is not nec-
essarily potent [5]. For this reason, they have been used in
combination with chemotherapy. The effect of chemother-
apy is known to be affected by the performance status (PS)
and nutritional and immune status of the patient [6–8].
Recently, Apetoh et al. [9] have presented basic research
evidence that tumor cells damaged by chemotherapy release
high mobility group box 1, which interacts with TLR4 to
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these activities contribute to the success of chemotherapy.
Clinically, these investigators also have reported earlier
relapse after combined anthracycline-based chemotherapy
and local radiotherapy in breast cancer patients with a
functionally deﬁcient TLR4 polymorphism, compared to
breast cancer patients with normal TLR4. These ﬁndings
show the importance of the host’s immune capacity during
chemotherapy, and suggest the importance of nonspeciﬁc
immune activation in cancer patients whose immune func-
tions are compromised.
Protein-bound polysaccharide K (PSK; KRESTIN
)i s
isolated and puriﬁed from the cultured mycelium of the
Basidiomycete Coriolus versicolor, has an average
molecular weight of approximately 100,000, and contains
18–38% protein. PSK exhibits antitumor activity against
various experimental tumors, and nonspeciﬁc immuno-
modulatory activity is considered the principal mechanism
of action of this agent [10]. PSK has been shown to regress
tumors clinically, and was approved in 1976 for the treat-
ment of cancers of the digestive organ, lung and breast.
Clinical use in Japan was started in 1977. After reevalua-
tion in 1989, PSK was approved for use in combination
with chemotherapy to prolong survival of patients with
gastric cancer (resected cases) or colorectal cancer (cura-
tively resected cases), and to prolong remission of patients
with small-cell lung carcinoma.
Along with advances in molecular biology and tumor
immunology, many investigators have conducted research
on the mechanisms of action of PSK and have built up
substantial knowledge. Studies on clinical effects are still
ongoing, mainly in accordance with the currently approved
indications. The present article reviews the recent devel-
opments in research on the biological mechanisms of PSK
and the major clinical results reported to date, to identify
the challenges for the future.
Biological mechanism of PSK
Although the importance of BRMs in cancer treatment
has been proven, better understanding of their mecha-
nisms of action is essential for optimal application of
these compounds. For PSK, three main mechanisms have
been revealed (Fig. 1)[ 11]. First, PSK improves host
immunocompetence by inhibiting the production of or
neutralizing immunosuppressive substances that are
increased in cancer. Second, PSK activates immune cells
such as lymphocytes, either directly or by regulating the
production of various cytokines. Third, PSK acts directly
on cancer cells. These mechanisms are considered to
support the clinical effectiveness of PSK in suppressing
cancer relapse.
Suppressed production or neutralization
of immunosuppressive factors (Table 1)
It is well known that various humoral factors induce
immunosuppression in cancer-bearing individuals. PSK
restores or attenuates this suppression, as demonstrated by
a larger number of reports showing abrogation of the
immunosuppressive effects of serum obtained from cancer-
bearing animals or cancer patients, inhibition of trans-
forming growth factor (TGF)-b production or antagonism
against TGF-b, and lowering of serum level of immuno-
suppressive acidic protein (IAP) and prostaglandin E2
(PGE2) production [12–17]. In addition, PSK has been
reported to possess antioxidant activity [18]. No other drug
exhibits such diverse actions as a single agent, and this is
the characteristic of PSK.
In an in vitro study using peripheral blood mononuclear
cells (PBMCs) from healthy volunteers, Yamaguchi et al.
[19] have reported that PSK enhances interleukin-2 (IL-2)-
induced proliferation of lymphokine-activated killer (LAK)
cells and their cytotoxic activity, and abolishes the TGF-b-
induced inhibition of LAK activity. They speculated that
PSK acted on TGF-b receptors to block the association
between TGF-b and its receptors. Thus, PSK seems to
inhibit the effects of TGF-b through various mechanisms
including suppression of TGF-b production, direct binding
with TGF-b, and acting on TGF-b receptors.
IL-10 shows various immunosuppressive activities, and
elevated serum levels of IL-10 have been reported as a
negative prognostic factor. Shibata et al. [20, 21] have
Fig. 1 Tumor microenvironment and actions of PSK.   Suppressed
production or neutralization of immunosuppressive factors. ` Acti-
vation of immune cells and regulation of cytokine production. ´
Direct action on tumor cells [induction of apoptosis, enhanced
expression of major histocompatibility complex (MHC) class I
antigen]. Adapted from Fujii [11]
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production was suppressed when PSK was added in vitro to
phytohemagglutinin (PHA)-stimulatedPBMCs frompatients
withadvancedcolorectalcancer,andthatIL-10productionby
PHA-stimulated PBMCs from advanced colorectal cancer
patientswasreducedafter2 monthsofimmunochemotherapy
with PSK, compared to that before treatment.
Tsujitani et al. [22] have examined the effect of PSK on
the expression of natural killer group 2D (NKG2D), a
receptor that activates CD8
? T cells and natural killer (NK)
cells. When PBMCs from healthy volunteers were co-cul-
tured with the human gastric cancer cell line MKN-45,
NKG2D expression on CD8
? T cells was downregulated,
while the addition of PSK restored NKG2D expression on
CD8
? T cells. The authors suggested that direct contact
between CD8
? T cells and gastric cancer cells was nec-
essary for the downregulation of NKG2D expression.
These ﬁndings raise interest on how PSK affects the
interaction between tumor cells and T cells.
The suppressive effect of tumor-derived factors on DCs
and the ability of PSK to overcome this effect have been
studied. Okuzawa et al. [23] have studied the in vitro dif-
ferentiation of peripheral blood CD14
? cells into DCs and
reportedthattheadditionoftheculturesupernatantofhuman
gastric cancer cells MKN-45P downregulated the surface
markers of DC maturation, decreased IL-12 production, and
increased apoptosis of DC. Addition of PSK restored all
these changes to the levels observed in the absence of the
culturesupernatant.Theseﬁndingssuggestthat,byreversing
the defective DC differentiation and function, PSK is able to
augment the subsequent immune response.
It is well known that surgical stress lowers the immune
response. PSK has been reported to attenuate the immuno-
suppression due to surgical invasion [24]. Using a mouse
laparotomy model, Ooshiro et al. [25] have found that con-
canavalin-A-stimulated interferon (IFN)-c (Th1 cytokine)
and IL-4 (Th2 cytokine) production by spleen cells was
decreased,andthedecrease inIFN-cwasespecially marked,
whichresultedinalowIFN-c/IL-4ratio.Inmicetreatedwith
PSK before laparotomy, the decreases in IFN-c and IL-4
production were ameliorated, the recovery of IFN-c pro-
ductionwasespeciallymarked,andtheIFN-c/IL-4ratiowas
restored. The resultant Th1/Th2 balance shifted to Th1
dominance. The ability of PSK to correct the Th1/Th2
imbalance, to be described later, could also work during the
perioperative period.
Many basic studies on the effects of the combined use of
PSK with chemotherapy have been reported. While che-
motherapy induces leukopenia and depresses immunity,
PSK inhibits these adverse effects [26]. The ability of PSK
to prevent chemotherapy-depressed immunity is one of the
mechanisms that accounts for the beneﬁt of PSK in com-
bined therapy. Kono et al. [27] have examined apoptosis of
peripheral blood T cells in gastric cancer patients treated
with oral ﬂuoropyrimidine agent tegafur–gimeracil–otera-
cil potassium (S-1; TS-1
), alone or in combination with
PSK. While an increase in T-cell apoptosis concomitant
with elevation of caspase-3 and Bax expression was
observed in patients treated with S-1 alone, these increases
were partially prevented in patients treated with S-1 and
PSK (Fig. 2). The mechanism has been speculated as
ensuing from the antioxidant activity of PSK, which
counteracts the increase in reactive oxygen species result-
ing from chemotherapy.
Regulation of immune cells and cytokine production
(Table 2)
Antitumor immune responses involve complex interactions
among various immune cells and cytokines (Fig. 3). PSK
exerts various effects on the immune cells, and its effects
on lymphocytes, helper T cells, CTLs, NK cells, LAK
Table 1 Suppressed production or neutralization of immunosuppressive factors
Immunosuppressive factors Subjects/animals/cells Key observations References
Cytokine PBMCs of healthy volunteers Abrogation of inhibition of LAK activities by
TGF-b
Yamaguchi [19]
PBMCs of colorectal cancer patients Suppression of IL-10 production Shibata [20, 21]
Cancer cell CD8
? T cells in peripheral blood of
healthy volunteers
Recovery of NKG2D expression
downregulated
by tumor cells
Tsujitani [22]
Tumor culture supernatant CD14
? cells in peripheral blood of
healthy volunteers
Prevention of defective maturation of DCs by
tumor culture supernatant
Okuzawa [23]
Surgical stress Mice Correction of Th1/Th2 imbalance Ooshiro [25]
Chemotherapy Gastric cancer patients Partial prevention of S1-induced peripheral
blood T-cell apoptosis
Kono [27]
PBMC peripheral blood mononuclear cell, LAK lymphokine-activated killer, TGF-b transforming growth factor-b, NKG2D natural killer (NK)
group 2D, DC dendritic cell, S-1 tegafur–gimeracil–oteracil potassium
10 Surg Today (2012) 42:8–28
123cells, and macrophages have been reported in numerous
publications [28–36]. In addition, the effects of PSK on the
production of various cytokines and nitric oxide (NO) have
been reported [37, 38].
Garcı ´a-Lora et al. [39, 40] have used the human NKL
cell line to study the intracellular signal transduction
pathway involved in the activation of NK cells by PSK.
PSK activates protein kinase C (PKC)d, PKCe, and extra-
cellular signal-regulated kinase (ERK)2 and ERK3, and
increases DNA binding of activator protein-1 (AP-1) and
cAMP response element (CRE) transcriptional factor. Asai
et al. [41] have shown that the addition of PSK in the
stimulation of mesenteric lymph node CD4
? T cells with
anti-CD3 antibody increased the production of IL-2, IFN-c,
and IL-4. They reported that the signaling pathway
involved the activation of linker for activation of T cells
(LAT), ERK1/2, nuclear factor of activated T cells, and
AP-1. Although the actions of PSK on immune cells differ
slightly depending on the cell type, these actions have
started to unfold at the level of the signal transduction
pathway. Further accumulation of data using different
immune cells under various conditions might provide a
comprehensive picture of the action of PSK.
As mentioned earlier, DCs play an important role in the
immune response. In the peripheral blood, DCs exist in an
immature state. Upon maturation by the actions of
inﬂammatory cytokines, they activate T cells and induce
acquired immunity. Kanazawa et al. [42] have reported that
the addition of PSK to cultures of peripheral blood CD14
?
mononuclear cells from healthy adults and advanced can-
cer patients with IL-4 and granulocyte-macrophage colony
stimulating factor for DC differentiation potentiates the
expression of maturation surface markers, such as CD83,
production of IL-12, and induction of CTLs. Using a
similar in vitro system, Ogihara et al. [43] have reported
similar results with the addition of PSK.
Fig. 2 Effect of oral administration of PSK on apoptosis of
circulating T cells induced by the anticancer drug S-1 in gastric
cancer patients. Adapted and modiﬁed from Kono et al. [27]
Table 2 Regulation of immune cells and cytokine production
Immune
cells
Subjects/animals/cells Key observations References
NK cells Human NK cell line Activation of PKCd, PKCe, ERK2, ERK3, AP-1 and
CRE transcriptional factor
Garcı ´a-Lora
[39, 40]
T cells CD4
? T cells in murine mesentric lymph node Activation of LAT, ERK1/2, NFAT and AP-1 Asai [41]
DCs CD14
? mononuclear cells in PBMC of healthy
volunteers
Promotion of maturation of DCs Kanazawa [42],
Ogihara [43]
Th1/Th2 PBMC of human healthy volunteers Increase of TNF-a production and decrease of IL-10
production by stimulation of human gastric cancer
cell lysate
Sugiyama [45]
Colorectal cancer patients Decrease of proportion of IL-10
? CD4
? T cells
(Th2) in peripheral blood
Yoshino [46]
B cells Human B cell line Enhancement of IgM production Maruyama [49]
Monocytes Human cord blood mononuclear cells Activation of T cells and induction of CTLs through
increase of IL-15 and LTB4 production by
monocytes in EBV-infected cultures
Liu [50–52],
Klein [53]
NKT cells Gastric cancer patients Decrease of CD57
? T cells in peripheral blood Akagi [54]
Others Murine peritoneal macrophages, etc. Inhibition of binding of LPS to LBP, protection of
LPS-induced lethality
Asai [55]
Mouse model of DSS and DMH-induced inﬂammatory
bowel disease and colorectal carcinogenesis
Antagonistic effects on inﬂammation and
carcinogenesis
Tsutsumi [57]
NK natural killer, PKC protein kinase C, ERK extracellular signaling regulated kinase, AP-1 activator protein-1, CRE cAMP-response element,
LAT linker for activation of T cells, NFAT nuclear factor of activated T cells, DC dendritic cell, PBMC peripheral blood mononuclear cell, TNF-a
tumor necrosis factor-a, CTL cytotoxic T lymphocyte, LTB4 leukotriene B4, EBV Epstein–Barr virus, LPS lipopolysaccharide, LBP LPS-binding
protein, DSS dextran sodium sulfate, DMH 1,2-dimethylhydrazine
Surg Today (2012) 42:8–28 11
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and naı ¨ve CD4
? T cells differentiate into Th1 or Th2 cells.
In a cancer-bearing state, the Th1/Th2 balance shifts to Th2
dominance; therefore, cellular immunity, which is the main
component of antitumor immunity, does not function efﬁ-
ciently [44]. Sugiyama et al. [45] have examined cytokine
production of PBMCs from healthy adults stimulated with
tumor antigen obtained by freezing and thawing a gastric
cancer cell line after 1 week. Addition of PSK did not
change IFN-c production, but increased tumor necrosis
factor-a (TNF-a) (Th1 cytokine) production and decreased
IL-10 (Th2 cytokine) production. Yoshino et al. [46]
treated colorectal cancer patients with PSK for 1 week
before surgery and examined the peripheral blood Th1/Th2
balance by ﬂow cytometry before and after treatment. After
PSK treatment, although the proportion of IFN-c-producing
CD4
? T cells (Th1) did not change, the proportion of IL-
10-producing CD4
? T cells (Th2) decreased. These studies
suggested that PSK appeared to act mainly to suppress Th2,
and PSK shifted the Th1/Th2 balance to Th1 dominance to
augment antitumor immunity.
Various monoclonal antibodies have been developed for
cancer treatment. PSK has been reported to augment anti-
body-dependent cell cytotoxicity [47]. The effect of PSK
on antibody production is considered to act via helper T
cells [48]. Maruyama et al. [49] have reported that PSK
directly enhances the proliferation and IgM production of
the human B cell line BALL-1, which suggests that PSK
also acts directly on the humoral immunity pathway to
potentiate acquired immunity.
Most of the studies on the effects of PSK on immune
cells or cytokine production have been conducted by tar-
geting individual immune cells or cytokines. In vivo,
however, the immune response is a cascade reaction that
involves many immune cells and cytokines. Liu et al. [50–
52] have investigated the effect of PSK on the immune
response against Epstein–Barr virus (EBV) infection, using
human cord blood mononuclear cells (CBMCs) that con-
tain various types of immune cells. The addition of PSK to
EBV-infected CBMCs increases expression of signaling
lymphocytic-activation molecule-associated protein (SAP),
which is an indicator of T- and NK cell activation. PSK
also induces EBV-speciﬁc CD4
? CTLs, and inhibits pro-
liferation of the potentially malignant EBV-infected B
cells. Liu et al. have further demonstrated that the presence
of monocytes and monocyte-derived IL-15 and leukotriene
B4 (LTB4) is necessary for the upregulation of SAP
expression by PSK. Klein et al. [53]. have reported that the
interaction between T cells activated by EBV-infected B
cells and monocytes activated by PSK occurs via CD40
ligand and CD40, and that these cells together with NK
cells activated by EBV-infected B cells progress to a
functionally activated state, which produces IL-15, IFN-c,
and LTB4 to induce CD4
? CTLs. IL-15 has been attracting
the most attention as an antitumor agent with potential for
clinical application (NCI Immunotherapy Agent Work-
shop, 2007), and studies have demonstrated that PSK
induces IL-15.
Akagi et al. [54] have examined the effect of postop-
erative immunochemotherapy with PSK on immune cells
in peripheral blood of gastric cancer patients at 3 months
after surgery, and have reported that administration of PSK
decreases the proportion of CD57
? T cells that mediate
suppressor T-cell functions.
On a slightly different note, Asai et al. [55] have
examined the NF-jB activity (indicated by luciferase
activity) when the pro-B cell line Ba/F3 transfected with
TLR-4 and MD-2 was stimulated with LPS. They have
reported that addition of PSK inhibited nuclear factor (NF)-
jB activity, which was caused by inhibition of binding
between LPS and LPS-binding protein (LBP) by PSK.
Administration of PSK also protected mice from LPS-
induced lethality, which indicates that PSK is useful for
controlling sepsis, which is also interesting from a clinical
viewpoint.
Association between chronic inﬂammation and cancer
development has been well described, and various factors
released from inﬂammatory cells have been reported to
exacerbate cancer [56]. Using a dextran sodium sulfate
(DSS) and 1,2-dimethylhydrazine-induced mouse model of
inﬂammatory bowel disease and colorectal carcinogenesis,
Fig. 3 Schematic representation of the antitumor immune responses
and actions of PSK. Tumor cells or their fragments are taken up by
APCs. Antigen peptides bind to MHC class I or II on the APCs. The
antigen peptides on MHC class I molecules activate naı ¨ve CD8
? T
cell, whereas the antigen peptides on MHC class II molecules activate
naı ¨ve CD4
? T cells (T-helper cell precursors). T-helper cell
precursors differentiate into Th1 and Th2 cells. Th1 cells produce
cytokines, including IL-2 and IFN-c. These cytokines induce
proliferation and activation of tumor antigen-speciﬁc CTLs, activa-
tion of NK cells and macrophages, and induction of LAK cells
12 Surg Today (2012) 42:8–28
123Tsutsumi et al. [57] have shown that PSK administration
reduced DSS-induced colitis-related mortality and inhib-
ited colorectal carcinogenesis, which indicates that PSK
possesses dual antagonistic effects against inﬂammation
and carcinogenesis. This study offers a new perspective on
the mechanism of the action of PSK.
Direct action on tumor cells (Table 3)
It has been demonstrated that PSK directly inhibits the
proliferation of cancer cells and induces apoptosis [24, 58,
59]. Also, PSK has been reported to upregulate the
expression of human leukocyte antigen (HLA) on human
gastric cancer cells [60]. Hattori et al. [61] have examined
the effects of PSK on 33 hematological malignant cell lines
and have reported that PSK strongly inhibits the prolifer-
ation of Namalwa (Burkitt lymphoma) cells and increases
apoptosis. It has been shown that inhibition of cell prolif-
eration by PSK is antagonized by the addition of galactose.
When Namalwa cells are treated with galactosidase, the
effect of PSK is enhanced, which suggests that the gal-
actose-containing structure of the Namalwa cell surface
plays an important role in the action of PSK. Jime ´nez-
Medina et al. [62] also have examined the effects of PSK
on seven human and mouse cancer cell lines. The inhibi-
tory effect of PSK on cell proliferation differs depending
on the cell line. For the AGS (human gastric cancer cell
line) cells in which a strong inhibitory effect is observed,
arrest of the cell cycle at G1, and increased apoptosis and
caspase-3 expression have been observed. From the above
results, it is apparent that PSK induces apoptosis of cancer
cells, but the effect seems to differ depending on the type
of cancer. Further studies should examine the properties of
cells in which apoptosis is induced by PSK.
PSK is well known to exhibit anti-metastatic activity in
various experimental metastasis models, and the mecha-
nism of action has been reported for each step of metastasis
[63]. Two new and interesting reports on the mechanism of
the anti-metastatic action of PSK, from the viewpoint of
TGF-b suppression, have been published. Zhang et al. [64]
have reported that PSK decreases the invasiveness of the
human pancreatic cancer cell line, NOR-P1, and the gastric
cancer cell line, MK-1P3, by multiple mechanisms that
include direct suppression of matrix metalloproteinase
(MMP) production, inhibition of the activation of latent
TGF-b, and indirect suppression of MMP production
through inhibition of TGF-b production. In recent years,
the association of epithelial–mesenchymal transition
(EMT) with invasion and metastasis of cancer cells has
been speculated, and TGF-b has been shown to play an
important role in the EMT process [65]. Hayashida et al.
[66] have treated SW837 cells (human colorectal cancer
cell line with normal TGF-b receptor and signal trans-
duction) with TGF-b followed by PSK, and have found that
nuclear translocation of the TGF-b signal transducer Sma-
and Mad-related protein 2 (Smad2) was inhibited, and that
the expression of genes including the TGF-b target gene
SERPINE-1 was also inhibited. In addition, they performed
Table 3 Direct actions on tumor cells
Targets of PSK action Animals/cells Key observations References
Apoptosis Burkitt lymphoma Induction of apoptosis Hattori [61]
Human gastric cancer cell line Induction of G1 arrest and apoptosis Jime ´nez-Medina
[62]
Metastasis Human pancreas or gastric cancer
cell line
Direct or indirect inhibition of MMP production
through TGF-b production and suppression of
latent TGF-b activation
Zhang [64]
Human colon cancer cell line Suppression of nuclear localization of Smad2;
decreased expression of TGF-b-targeted gene;
inhibition of TGF-b-induced EMT
Hayashida [66]
Neoangiogenesis HUVEC, rat Inhibition of bFGF-induced cell proliferation
through direct binding to bFGF
Wada [68]
Gene expression Human colorectal cancer cell line Upregulation of expression of MRP3, lymphotactin,
transgelin and pirin
Yoshikawa [70]
Combination with
chemotherapy
Human pancreas cancer cell line Inhibition of docetaxel-induced NF-jB activation
and cIAP-1 expression, and enhancement of
apoptosis induced by docetaxel
Zhang [71]
Human gastric cancer cell line Inhibition of docetaxel-induced NF-jB activation
and survivin expression
Kinoshita [72]
MMP matrix metalloproteinase, TGF-b transforming growth factor-b, EMT epithelial–mesenchymal transition, HUVEC human umbilical vein
endothelial cells, bFGF basic ﬁbroblast growth factor, MRP3 multidrug resistance protein 3, NFjB nuclear factor-jB, cIAP-1 cellular inhibitor
of apoptosis protein
Surg Today (2012) 42:8–28 13
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that PSK inhibited EMT.
PSK is known to inhibit angiogenesis [67] and new
results on the mechanism have been reported. Wada et al.
[68] have shown that PSK administration inhibits basic
ﬁbroblast growth factor (bFGF)-induced angiogenesis in
rats, and from studies on human umbilical vein endothelial
cells, they have speculated that the mechanism is due to
direct binding of PSK with bFGF, which results in sup-
pression of bFGF-induced proliferation of endothelial cells.
The effect of PSK on vascular endothelial growth factor-
induced angiogenesis [69] should also be examined.
Comprehensive gene expression analysis of PSK-treated
cancer cells has been attempted. Yoshikawa et al. [70] have
usedcDNAmicroarraystoanalyzethe invitroeffectofPSK
on the gene expression proﬁle of the human colorectal ade-
nocarcinoma cell line HCT116, the proliferation of which is
inhibited by PSK. After PSK treatment, approximately 450
genes showed altered expression. The expression of genes
that were signiﬁcantly altered was examined further in two
cell lines, HCT116 and SW480, using RT-PCR. Multidrug
resistanceprotein3,lymphotactin,transgelin,andpirinwere
upregulated in both cell lines. Studies on the relationship
between PSK-induced altered gene expression and the bio-
logical response are anticipated.
Even when used in conjunction with chemotherapy,
PSK directly acts on cancer cells to enhance the effect of
combined therapy. Zhang et al. [71] have studied the effect
of PSK and low-dose docetaxel on proliferation of the
human pancreatic cancer cell line NOR-P1, and have
reported the mechanisms as follows. Docetaxel induces
apoptosis, but at the same time it also activates NF-jB and
induces cellular inhibitor of apoptosis protein (cIAP)-1
expression, to suppress the induction of apoptosis. PSK
inhibits the docetaxel-induced NF-jB activation to
enhance induction of apoptosis. Kinoshita et al. [72] also
have reported that PSK inhibits docetaxel-induced NF-jB
activation and survivin expression in the human gastric
cancer cell line TMK-1, and enhances antitumor effect of
docetaxel through inhibition of survivin expression in
tumor tissue in a xenograft model.
Clinical effect of PSK
Clinical trials of PSK were started from around 1972, and
the early trials demonstrated the effectiveness of PSK as
monotherapy or in combination with chemotherapy, which
led to the approval of PSK for clinical use in Japan. In
1980, the criteria for the evaluation of immunotherapy for
malignant tumors were published. According to these cri-
teria, immunotherapy should be used in combination with
other therapies such as chemotherapy, and the evaluation of
its effect should include statistically estimating the overall
survival (OS) or disease-free survival (DFS), based on
randomized control trials (RCTs) using the base therapy as
a control [73]. These criteria apply also to PSK. RCTs were
planned and conducted, and submitted for reevaluation,
which resulted in reapproval for current indications. In
addition, the efﬁcacy of PSK has been veriﬁed in multiple
meta-analyses.
Gastric cancer (Tables 4, 6)
Anticancer chemotherapy can be classiﬁed into two types:
systemic chemotherapy for unresectable metastatic or
recurrent cancer, and adjuvant chemotherapy for sup-
pressing postoperative relapse. Almost all the clinical
results of PSK belong to the latter type. As a study of the
former type, Nakao et al. [74] have conducted a clinical
trial to determine the efﬁcacy of PSK in 54 patients with
unresectable or postoperative recurrent gastric cancer.
Patients were treated with intravenous mitomycin C
(MMC) and 5-ﬂuorouracil (5-FU) twice weekly for
2 weeks, followed by intravenous MMC/5-FU once weekly
plus oral PSK 3 g/day on consecutive days (chemotherapy
? PSK group), or MMC/5-FU alone (chemotherapy
group). They reported that, although the response rates
were not signiﬁcantly different between the two groups, the
survival duration was signiﬁcantly (P = 0.03) prolonged in
the chemotherapy ? PSK group. Although unresectable,
metastatic, and recurrent gastric cancers are not included in
the approved indications for PSK at present, this study does
suggest a direction for the potential use of PSK.
The results of postoperative adjuvant chemotherapy for
gastric cancer have been reviewed by Maehara et al. [75].
In Japan, many controlled trials of postoperative adjuvant
chemotherapy compared with surgery alone were con-
ducted from the 1960s, but few studies have reported sig-
niﬁcant results in favor of postoperative adjuvant
chemotherapy. Kondo et al. [76] have conducted a double-
blind trial on 144 stage III surgical patients randomized to
receive oral PSK 1–3 g/day from 10–15 days after surgery
until relapse or distant metastasis (PSK group), or placebo
(control group). They reported that PSK treatment signiﬁ-
cantly prolonged DFS. Their results indicate that PSK,
even when used alone, is effective in some patients,
although PSK monotherapy is not an approved usage at
present. In the study of Maehara et al. [77], 225 patients
who underwent histologically curative resection of
advanced gastric cancer were treated postoperatively with
intravenous MMC once every 3 months for 1 year, toge-
ther with oral tegafur and PSK from 7 to 10 days after
surgery, for long-term (postoperative long-term cancer
chemotherapy group; PLCC), or surgery alone. The long-
term (15-year) survival rate was 56.9% in the PLCC group
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123and 45.7% in the surgery group, which showed a signiﬁcant
(P = 0.0351) survival beneﬁt in the PLCC group (Fig. 4).
Since a subset analysis of multiple clinical trials has
shown the effectiveness of postoperative adjuvant chemo-
therapy compared with surgery alone, studies from the
1980s have compared efﬁcacy between different adjuvant
chemotherapies. The effectiveness of PSK as an adjuvant
therapy for gastric cancer has been evaluated mainly during
this period, by comparing chemotherapy ? PSK with
chemotherapy alone. To examine the effectiveness of im-
munostimulators, the Co-operative Study Group of Surgi-
cal Adjuvant Chemotherapy for Gastric Cancer (SACG)
divided Japan into six blocks in 1978, and each block
conducted multicenter RCTs independently in patients with
resected gastric cancer, excluding the patients with muco-
sal cancer having no lymph node metastasis, and compared
immunochemotherapy with chemotherapy [78]. In the
Chugoku/Kyushu block, 579 patients who underwent
curative surgery were given intravenous MMC on the day
of and 1 day after surgery, followed 2 weeks later by oral
PSK 3 g/day plus tegafur (chemotherapy ? PSK group), or
PSK alone (PSK group) or tegafur alone (chemotherapy
group) for 1 year. Niimoto et al. [79] have reported that the
5-year OS rate in the three groups was 71.7, 64.1, and
58.5%, respectively, and a signiﬁcant difference (P\0.05)
was detected in a three-group comparison. In two-group
comparisons, the survival rate was signiﬁcantly (P\0.01)
higher in the chemotherapy ? PSK group than in the
Table 4 RCTs of postoperative adjuvant chemotherapy with PSK for resected gastric cancer
References
or trial
Stage No. of
patients
Treatment Percent survival/years P value Suggestive data (percent
survival/years)
Kondo [76] III 72 A: PSK
B: Placebo
Improvement of DFS Signiﬁcant
72
Maehara [77] Advanced stage 137 A: MMC ? FT ? PSK
B: Surgery alone
56.9/15
45.7/15
0.0351
118
Niimoto [79]
SACG
Chugoku/
Kyushu
a 191 A: MMC?FT?PSK
B: MMC?PSK
C: MMC?FT
71.7/5
64.1/5
58.5/5
3 groups
\0.05
A versus C
\0.01
189
199
Kondo [80]
SACG
Chubu
a 145 A: FT?PSK
B: FT
64.1/8
61.0/8
0.410 A: 86 cases
b, 56.8/8
B: 90 cases
b, 43.6/8
P = 0.071
159
Kondo [82]
TGOG
Advanced stage 47 A: CQ?PSK
B: CQ
Not described 0.827 A: 30 cases
c, 43.4/7
B: 32 cases
c, 32.3/7
P = 0.153
49
Nakazato [83]
SIP
T2, T3 124 A: MMC?5-FU?PSK
B: MMC?5-FU
73.0/5
60.0/5
0.044
129
Hattori [13]
JFMC01
II–III 1,426 A: MMC?FT?PSK
B: MMC?FT
C: MMC?FT?OK-432?PSK
D: MMC?FT?OK-432
71.6/3
69.6/3
69.1/3
68.7/3
NS
1,357
1,338
1,363
Ogawa [84] I-IV 56 A: MMC?HCFU?PSK
B: MMC?HCFU
80.2/5
81.1/5
0.811
55
JFMC05 T3, T4 215 A: FT?PSK
B: FT?OK-432
C: FT
52.8/5
49.3/5
47.0/5
NS
219
217
JFMC11 T1, T2 114 A: CPA?PSK
B: surgery alone
84.8/5
83.3/5
NS
112
DFS disease-free survival, MMC mitomycin C, FT tegafur, CQ carboquone, T tumor, 5-FU 5-ﬂuorouracil, NS not signiﬁcant, OK-432 picibanil,
HCFU carmofur, CPA cyclophosphamide
a Excluding mucosal cancer having no lymph node metastasis
b Tumors with serosal invasion
c Tumors with serosal invasion with limited lymph node metastasis
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123chemotherapy group. The Chubu block also enrolled
curative surgical cases. The subjects were randomized into
two groups according to treatment from 2 weeks after
surgery: oral tegafur for 3 months followed by PSK for
2 months (one course) for two courses or more (chemo-
therapy ? PSK alternating therapy group), and tegafur for
3 months followed by no treatment for 2 months for two
courses or more (intermittent chemotherapy group). Kondo
et al. [80] have reported that a subset analysis of subjects
having tumors with serosal invasion showed an improved
8-year survival rate in the chemotherapy ? PSK alternating
therapy group (56.8%) compared with the intermittent
chemotherapy group (43.6%) (P = 0.071). Sakamoto et al.
[81] also reported that subset analysis of subjects with
preserved cellular immunity, as shown by a positive puri-
ﬁed protein derivative of tuberculin (PPD) skin test before
surgery in this trial, showed an improved survival rate in
the chemotherapy ? PSK alternating therapy group com-
pared with the intermittent chemotherapy group
(P = 0.254). In addition, Kondo et al. [82] have reported
that a subset analysis of subjects having tumors with
serosal invasion and limited lymph node metastasis showed
an improved 7-year survival rate in the chemotherapy
(carboquone) ? PSK alternating therapy group (43.4%)
compared with the intermittent chemotherapy group
(32.3%) (P = 0.153) (Tokai Gastrointestinal Oncology
Group; TGOG). Based on these ﬁndings, the Study Group
of Immunochemotherapy with PSK for gastric cancer (SIP)
conducted a multicenter RCT on 253 curative surgery cases
with T2 or T3 lesions and positive preoperative PPD skin
tests. After surgery, MMC was administered intravenously.
Four weeks later, one group was given PSK 3 g/day for
4 weeks and then oral 5-FU for 4 weeks (one course) for a
total of 10 courses (chemotherapy ? PSK alternating
therapy group), and the other group was given tegafur
alone (intermittent chemotherapy group). As reported by
Nakazato et al. [83], the 5-year OS rate in the PSK ?
chemotherapy alternating therapy and intermittent chemo-
therapy groups was 73.0 and 60.0%, respectively
(P = 0.044), and the DFS rate was 70.7 and 59.4%,
respectively (P = 0.047), which showed signiﬁcantly bet-
ter survival with PSK ? chemotherapy alternating therapy
(Fig. 5).
Table 5 RCTs of postoperative adjuvant chemotherapy with PSK for resected colorectal cancer
References Stage No. of
patients
Treatment Percent survival/years P value Suggestive data
(percent survival/years)
Torisu [88] Stage III, IV 55 A: PSK
B: Placebo
Improvement of
DFS and OS
\0.05
56
Takashima [89] Dukes’ A–C 53 A: MMC ? FT suppo ? PSK
B: MMC ? FT suppo
91.4/6
80.8/6
0.139 A: 30 cases
a, 90.2/6
B: 39 cases
a, 70.9/6
P\0.05
71
Mitomi [90] Stage III 221 A: MMC?5-FU?PSK
B: MMC?5-FU
78.5/5
69.7/5
0.0325
227
Ito [91] Dukes’ C 220 A: 5-FU?PSK
B: 5-FU
79.6/7
75.6/7
0.081 SCD
A: 83.4/7
B: 78.5/7
P = 0.019
221
Ohwada [92] Stage II, III 137 A: MMC?UFT?PSK
B: MMC?UFT
81.8/5
72.1/5
0.056 DFS
A: 73.0/5
B: 58.8/5
P=0.016
68
DFS disease-free survival, OS overall survival, MMC mitomycin C, FT tegafur, 5-FU 5-ﬂuorouracil, SCD survival for cancer-related death, UFT
tegafur-uracil
a Lymphatic vessel invasion (?)
Fig. 4 Effect of PLCC plus PSK on 15-year OS in patients with
advanced gastric cancer after curative resection. Adapted and
modiﬁed from Maehara et al. [77]
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123Among the RCTs that have examined the efﬁcacy of
PSK in combination with chemotherapy, some could not
conﬁrm the efﬁcacy of PSK. The Cooperative Project No. 1
of the Japanese Foundation for Multidisciplinary Treat-
ment of Cancer (JFMC01) was a large-scale clinical trial
that enrolled 7,637 patients in 267 facilities. To clarify the
effectiveness of PSK and OK-432, two widely used
immunostimulatory compounds, patients were adminis-
tered MMC intravenously on the day of and 1 day after
surgery. From 2 weeks after surgery, the patients received
the following treatments for 8 months: oral tegafur only,
oral tegafur ? PSK 3 g/day, tegafur ? intradermal or
intramuscular OK-432 0.5–5 KE/day, or tegafur ? PSK ?
OK-432. The 3-year survival rate tended to be higher in
groups administered PSK and/or OK-432 [13]. The
immune status of the patients was evaluated simulta-
neously, using the effect of patients’ serum on the PHA
blastogenesis reaction of mouse lymphocytes as an indi-
cator. Hattori et al. [13] have reported that the 4-year
survival rate was signiﬁcantly (P = 0.012) higher in
patients with a high stimulation index, and many patients in
the PSK-treated group had a high index.
Ogawa et al. [84] (Kumamoto Gastrointestinal Immun-
ochemotherapy Study Group; KGSG) enrolled 111 patients
who underwent curative surgery and treated them 2 weeks
after surgery with oral carmofur and PSK 3 g/day (che-
motherapy ? PSK group), or carmofur alone (chemother-
apy group) for 1 year, and observed no difference in 5-year
survival rate between the two groups. In the JFMC05 trial,
651 patients with resected T3 or T4 gastric cancer received
postoperative tegafur ? PSK, tegafur ? OK-432, or tegafur
alone after surgery. The 5-year survival rate was 52.8% in
the tegafur ? PSK group, 49.3% in the tegafur ? OK-432
group, and 47.0% in the tegafur alone group. Although the
rate was apparently higher in the tegafur ? PSK group, the
difference was not signiﬁcant (http://jfmc.or.jp/product/
prod04/index.html). In the JFMC11 trial, 228 patients with
resected T1 or T2 gastric cancer were enrolled. One group
received one dose of cyclophosphamide (CPA) and PSK
3 g/day for 1 week before surgery, as well as PSK for
6 months after surgery, and the other group had surgery
only. The survival rate did not differ between the two
groups (http://jfmc.or.jp/product/prod04/index.html).
The effectiveness of PSK as postoperative adjuvant
therapy has been shown in meta-analysis. Oba et al. [85]
have identiﬁed 47 papers that have compared the survival
duration of chemotherapy ? PSK with chemotherapy alone
in patients who underwent curative surgery for gastric
cancer. They excluded duplicated data and selected eight
trials of high quality to conduct a meta-analysis. The
hazard ratio of 5-year survival was 0.88 [95% conﬁdential
interval (CI): 0.79–0.98, P = 0.018] (Fig. 6), which veri-
ﬁed that chemotherapy ? PSK improved survival in
patients with curatively resected gastric cancer.
As shown above, the efﬁcacy of PSK as postoperative
adjuvant therapy has been veriﬁed by a large number of
studies. Furthermore, Sugimachi et al. [86] have studied
196 patients with curatively resected, poorly differentiated
stage II–IV gastric cancer and treated them with MMC and
PSK 3 g/day as the basal postoperative therapy, in com-
bination with two doses of UFT. The recurrence rate was
signiﬁcantly reduced and the 5-year DFS and cause-spe-
ciﬁc survival rates were signiﬁcantly (P\0.05) increased
in the high-dose UFT (12 mg/kg) group compared with the
moderate-dose (8 mg/kg) group. They concluded that
combination therapy with high-dose UFT plus PSK
improved the postoperative outcome, with no increase in
toxicity for poorly differentiated gastric cancer.
After 1990, RCTs were again conducted to examine the
effectiveness of postoperative adjuvant chemotherapy
compared to surgery alone. At present, TS-1 has become
the standard agent for postoperative adjuvant chemother-
apy for gastric cancer in Japan [87].
For PSK, the Hokuriku-Kinki Immunochemotherapy
Study Group Gastric Cancer (HKIT-GC) group is currently
conducting a clinical trial on patients with curatively
resected stage II and IIIA gastric cancer. Two groups are
being compared: one group is receiving TS-1 for 2 weeks
on and 1 week off for 6 months, followed by TS-1 for
2 weeks on and 2 weeks off for 6 months (TS-1 group);
and another group is receiving PSK in combination with
the above regimen for 1 year (TS-1 ? PSK group)(
http://clinicaltrials.gov/ct2/home). Another ongoing trial
conducted by Tokyo Metropolitan Oncology Group
(TMOG) is recruiting curatively resected stage II and III
gastric cancer patients and comparing the outcome of
treatment with TS-1 alone for 4 weeks on and 2 weeks off
(TS-1 group) and PSK in combination with the above
regimen (TS-1 ? PSK group) for 1 year (http://clinical
trials.gov/ct2/home).
Fig. 5 Effect of adjuvant immunochemotherapy with PSK on 5-year
overall survival in patients with T2 or T3 gastric cancer after curative
resection. Adapted and modiﬁed from Nakazato et al. [83]
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123Colorectal cancer (Tables 5, 6)
The prognosis of surgical treatment for colon and rectal
cancers is poor for stage III or higher colon cancer and
stage II or higher rectal cancer. For these advanced cancers,
postoperative adjuvant therapy is considered necessary. In
Japan, many trials have examined the effectiveness of
postoperative adjuvant chemotherapy for colorectal cancer
using oral ﬂuorinated pyrimidine agents, compared with
surgery alone, but few studies have reported the effec-
tiveness of these agents.
The efﬁcacy of PSK on colorectal cancer has been
evaluated as postoperative adjuvant therapy. Torisu et al.
[88] have conducted a double-blind trial on patients with
curatively resected stage III and IV colorectal cancer and
compared PSK 1–3 g/day given after surgery until relapse
or distant metastasis (PSK group) and placebo (control
group). They reported signiﬁcantly better OS (P\0.05)
and DFS (P\0.05) rates in the PSK group.
Thereafter, comparative studies of chemotherapy versus
chemotherapy ? PSK have been conducted. The Colorectal
Cancer Chemotherapy Group in Hokuriku has conducted a
multicenter RCT of 124 patients with curatively resected
advanced colorectal cancer and administered intravenous
MMC on the day of and 1 day after surgery. The patients
were randomized to receive tegafur suppository and oral
PSK 3 g/day (chemotherapy ? PSK group) or tegafur sup-
pository alone (chemotherapy group) from 1–2 weeks after
surgeryfor1 year.Takashimaetal.[89]havereportedthatin
lymphatic vessel invasion (?) cases, the 6-year OS rates for
thetwogroupswere90.2and70.9%,whichwassigniﬁcantly
(P\0.05) higher in the chemotherapy ? PSK group. The
Cooperative Study Group of Surgical Adjuvant Immun-
ochemotherapy for Cancer of Colon and Rectum (Kanaga-
wa) has conducted a multicenter RCT on 448 patients who
underwentmacroscopic curative surgery forstage III and IV
colorectalcancer.AftertreatmentwithintravenousMMCon
the day of and 1 day after surgery, the subjects were ran-
domized 2–3 weeks later to receive oral 5-FU for at least
6 monthsandPSKforatleast3 years(chemotherapy?PSK
group), or 5-FU alone (chemotherapy group). Mitomi et al.
[90] have reported that the 5-year DFS (P = 0.0302) and
survival (P = 0.0325) rates were signiﬁcantly higher in the
chemotherapy ? PSK group compared to the chemotherapy
group (5-year DFS rates: 72.3 vs. 63.2%; 5-year survival
rates: 78.5 vs. 69.7%).
The Study Group of Immunochemotherapy with PSK
for colon cancer has conducted a multicenter RCT on 441
colon cancer patients with macroscopic Dukes’ C cancer
after curative resection. After surgery, continuous intrave-
nous infusion of 5-FU was administered and the patients
were randomized at 4 weeks after surgery to receive oral
PSK 3 g/day for 4 weeks, followed by oral 5-FU for
4 weeks (one course) for a total of 10 courses (chemo-
therapy ? PSK alternating therapy), or 5-FU alone (inter-
mittent chemotherapy). Ito et al. [91] have reported that the
7-year cancer death-free survival rate was signiﬁcantly
(P = 0.019) higher in the chemotherapy ? PSK alternating
therapy arm (83.4%) than in the intermittent chemotherapy
arm (78.5%), with a risk reduction of 40.8%.
The Gunma Oncology Study Group has conducted a
multicenter RCT on 205 patients with curatively resected
Fig. 6 Meta-analysis of the
effect of adjuvant
immunochemotherapy with
PSK on OS in patients with
gastric cancer after curative
resection. JMTC, Japanese
Foundation for
Multidisciplinary Treatment of
Cancer; MF mitomycin C plus
tegafur, MHCFU mitomycin C
plus HCFU, MFU mitomycin C
plus 5-ﬂuorouracil, MT
mitomycin C plus tegafur,
T tegafur. Adapted from Oba
et al. [85]
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123stage II or III colorectal cancer. Two weeks after intrave-
nous MMC (given on the day of surgery and the following
day), one group received oral UFT and PSK 3 g/day for
2 years (chemotherapy ? PSK group), and the other group
received oral UFT alone (chemotherapy group). Ohwada
et al. [92] have reported that the 5-year DFS rate was
signiﬁcantly (P = 0.016) higher in the chemotherapy ?
PSK group (73.0%) compared with the chemotherapy
group (58.8%). Combined therapy with PSK reduced the
risk of recurrence by 43.6%. The mean DFS period was
signiﬁcantly (P = 0.031) prolonged in the chemotherapy
? PSK group (50.3 months) compared with the chemo-
therapy group (40.0 months). The 5-year OS rate was
higher in the chemotherapy ? PSK group (81.8%) than in
the chemotherapy group (72.1%), although there was no
signiﬁcant difference (P = 0.056). Furthermore, they
reported an adverse event rate of 15.1% for both groups,
with no grade 3 or 4 events. They concluded that, com-
pared with combined intravenous 5-FU and leucovorin
(LV) treatment, for which many grade 3 or higher adverse
events have been reported, UFT ? PSK therapy was a
useful adjuvant therapy that did not require frequent hos-
pital visits and had few adverse reactions.
Sakamoto et al. [93] have performed a meta-analysis of
three RCTs that were conducted and published between
1980 and 2004 on curatively resected colorectal cancer
patients and compared chemotherapy ? PSK with che-
motherapy alone. The overall survival risk ratio was 0.71
(95% CI 0.55–0.90, P = 0.006) and the DFS risk ratio was
0.72 (95% CI 0.58–0.90, P = 0.003), which showed a
signiﬁcant survival beneﬁt of combined therapy with PSK
(Fig. 7). Their study conﬁrms the signiﬁcance of using
PSK in postoperative adjuvant therapy for colorectal can-
cer and opens the possibility of developing improved
therapy for colorectal cancer.
Several ongoing studies on PSK have been examining
various combination therapy regimens used as postopera-
tive adjuvant therapy. The Hokkaido Gastrointestinal
Cancer Study Group, Colorectal Adjuvant Chemotherapy
Division (HGCSG-CAD) has been comparing 6 months
UFT ? LV therapy (UFT ? LV group), 6-month UFT ?
LV with UFT extended for 1 year (UFT ? LV/UFT
Table 6 Ongoing RCTs with PSK
Title of the study Organizations/sponsors Tumor Stage Treatment regimen
Randomized controlled study of
postoperative adjuvant therapy for gastric
cancer using TS-1 or TS-1 ? PSK
Hokuriku-Kinki Immunochemotherapy
Study Group Gastric Cancer (HKIT-GC)
Gastric
cancer
II, IIIA TS-1(1 year)
TS-1?PSK (1 year)
Study of TS-1 or TS-1 ? PSK for gastric
cancer patients
Tokyo Metropolitan Oncology Group
(TMOG)
Gastric
cancer
II, III TS-1 (1 year)
TS-1?PSK (1 year)
Randomized phase III adjuvant study
for stage III colorectal cancer
Hokkaido Gastrointestinal Cancer Study
Group, Colorectal Adjuvant Chemotherapy
Division (HGCSG-CAD)
Colorectal
cancer
III UFT ? LV (5 courses)
UFT ? LV (5
courses)/UFT
(1 year)
UFT ? LV ? PSK (5
courses)/UFT ? PSK
(1 year)
Uracil and tegafur/leucovorin (UFT/LV)
versus UFT/LV?PSK for stage IIIa/IIIb
colorectal cancer
Iwate Clinical Oncology Group, Colorectal
Cancer (ICOG-CC)
Colorectal
cancer
IIIa, IIIb UFT ? LV
UFT ? LV ? PSK
Phase III trial comparing UFT ? PSK to
UFT ? LV in stage IIB, III colorectal
cancer
Multicenter Clinical Study Group of Osaka,
Colorectal Cancer Treatment Group
(MCSGO-CCTG)
Colorectal
cancer
IIB, III UFT?PSK (1 year)
UFT?LV (6 months)
Phase III trial comparing surgery alone
to UFT ? PSK in stage II rectal cancer
Japanese Foundation for Multidisciplinary
Treatment of Cancer
Rectal
cancer
II Surgery alone
UFT ? PSK (1 year)
TS-1 tegafur–gimeracil–oteracil potassium, UFT tegafur-uracil, LV leucovorin
Fig. 7 Meta-analysis of the effect of adjuvant immunochemotherapy
with PSK on OS in patients with colorectal cancer after curative
resection. Adapted from Sakamoto et al. [93]
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123group), and PSK added on to the latter regimen (UFT ? LV
? PSK/UFT ? PSK group) in patients with curatively
resected stage III colorectal cancer (http://clinicaltrials.
gov/ct2/home). The Iwate Clinical Oncology Group,
Colorectal Cancer (ICOG-CC) trial has been comparing
UFT ? LV with UFT ? LV ? PSK in patients with
curatively resected stage IIIa and IIIb colorectal cancer
(http://clinicaltrials.gov/ct2/home). The Multicenter Clini-
cal Study Group of Osaka, Colorectal Cancer Treatment
Group (MCSGO-CCTG) has been comparing UFT ? PSK
(1 year) with UFT ? LV (6 months) in patients with
curatively resected stage IIB and III colorectal cancer
(http://clinicaltrials.gov/ct2/home). In the JFMC38-0901
trial, the effect of 12 months UFT ? PSK therapy com-
pared with surgery alone is being evaluated in patients with
curatively resected stage II rectal cancer (http://upload.
umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=search&action=
list&language=J).
Lung cancer (Table 7)
Konno et al. [94] have compared the combination of
intravenous vincristine (VCR), cyclophosphamide (CPA),
and MMC once weekly for 8 weeks with or without
8–10 Gy radiotherapy (chemotherapy/radiotherapy group)
with the combination of PSK 3 g/day added to the above
regimen (chemotherapy/radiotherapy ? PSK group) in 97
patients with small-cell lung carcinoma. Although the
response rates did not differ between the two groups, the
median response duration was signiﬁcantly (P = 0.042)
longer in the chemotherapy/radiotherapy ? PSK group
(25 weeks) than in the chemotherapy/radiotherapy group
(13 weeks). Evidence for combined use of PSK and cur-
rently used chemotherapy regimen for extensive-stage
small-cell lung cancer is anticipated; therefore, the
Research Network for Chemotherapy of Lung Cancer
(RNCLC) has been conducting a phase II trial to examine
the effect of cisplatin ? irinotecan ? PSK compared with
historical controls (http://clinicaltrials.gov/ct2/home).
To examine the usefulness of PSK as postoperative
adjuvant therapy for lung cancer, Ikeda et al. [95] have
studied 113 patients with non-small cell lung cancer ran-
domized after surgery into three groups: chemotherapy
with VCR, MMC, methotrexate, CPA or 5-FU combined
with PSK 3 g/day (chemotherapy ? PSK group); chemo-
therapy combined with OK-432 (chemotherapy ? OK-432
group); and chemotherapy alone (chemotherapy group).
The three-group comparison detected a signiﬁcant differ-
ence (P\0.05) in the 4-year survival, and the two-group
comparisons found a signiﬁcant difference (P\0.05)
between the chemotherapy ? PSK and chemotherapy
groups.
Hayakawa et al. [96] have investigated PSK therapy in
188 patients with non-small cell lung cancer, mainly stages
I–III squamous cell cancer, who had achieved complete or
partial response after radiotherapy. The patients were ran-
domized to receive adjuvant treatment with PSK inter-
mittent administration of 3 g/day for 2 weeks followed by
2 weeks off, or no adjuvant treatment. The 5-year survival
rate was signiﬁcantly (P\0.001) higher in the group
given PSK. As demonstrated in these studies, PSK is
effective also for non-small cell lung cancer.
Table 7 RCTs of chemotherapy and/or radiotherapy with PSK for lung cancer
References Tumor characteristics No. of
patients
Treatment Response rate (%)
or percentage
survival/year
P value Suggestive data
Duration of tumor
response
Konno
[94]
Small-cell lung cancer 48 A: VCR?CPA?MMC
(radiation)?PSK
B: VCR?CPA?MMC (radiation)
45
46
NS A: 25 weeks
B: 13 weeks
P = 0.042
49
Ikeda [95] Non-small cell lung cancer
stage I–IV
27 A: VCR?MMC?MTX (CPA,
5-FU)?PSK
B: VCR?MMC?MTX (CPA,
5-FU)?OK-432
C: VCR?MMC?MTX (CPA,
5-FU)
55.9/4
36.7/4
34.7/4
3 groups
\0.05
A versus
C
\0.05
39
47
Hayakawa
[96]
Non-small cell lung cancer
Stage I–III
77 A: Radiation?PSK
B: Radiation
30/5
9/5
\0.001
111
VCR vincristine, CPA cyclophosphamide, MMC mitomycin C, NS not signiﬁcant, MTX methotrexate, 5-FU 5-ﬂuorouracil, OK-432 picibanil
20 Surg Today (2012) 42:8–28
123Other clinical uses (Tables 8, 9)
A number of reports on the effects of PSK on cancers not
included in the approved indications have been published.
In one report, nasopharyngeal carcinoma patients who had
undergone radiotherapy or radiotherapy ? chemotherapy
were given PSK or no further treatment. The 5-year sur-
vival rate was signiﬁcantly (P = 0.043) improved in the
PSK-treated group compared to the non-PSK-treated group
[97]. Patients with primary or relapsed superﬁcial bladder
cancer were randomized after surgery to receive PSK,
chemotherapy with carboquone, or chemotherapy ? PSK,
and were compared with surgery alone. The 3-year DFS
rate was signiﬁcantly better in the PSK-treated group
compared with surgery alone (P = 0.008) or the chemo-
therapy-treated group (P = 0.006) [98]. In esophageal
cancer patients treated postoperatively with radiotherapy,
or radiotherapy combined with PSK or radiotherapy ?
chemotherapy (bleomycin, or pepleomycin ? tegafur), or
radiotherapy ? chemotherapy combined with PSK, the
5-year survival tended to be prolonged in the radiotherapy
? chemotherapy ? PSK group compared with the radio-
therapy ? chemotherapy group, although the difference
was not signiﬁcant (P = 0.1034) [99]. Breast cancer
patients were treated with postoperative chemotherapy
(5-FU ? CPA ? MMC ? prednisolone) with or without
PSK. The 10-year OS rate tended to be higher
(P = 0.0706) in the PSK-treated group compared with the
group given chemotherapy alone [100]. Although BRMs
such as PSK have a direct effect on tumors, their major
action is to enhance and modulate the immune response,
which can account for a reasonable degree of effectiveness
against various tumor types.
Few adverse reactions from the use of PSK have been
reported, and most of them are gastrointestinal symptoms
with no report of serious toxicity such as bone marrow
suppression, or liver or renal function impairment [76, 88,
101]. PSK is relatively non-toxic and it has been reported
to attenuate the adverse reactions or immunosuppression
induced by chemotherapy or radiotherapy [102, 103].
Furthermore, Yoshimura et al. [104] have examined the
quality of life (QOL) of 20 patients with unresectable stage
III and IV lung adenocarcinoma treated with chemotherapy
(cisplatin ? vindesine) ? PSK or chemotherapy alone, and
found that good QOL was maintained in the patients
treated with chemotherapy ? PSK. Motai et al. [105] have
investigated the frequency of prescription of analgesics for
cancer pain in head and neck cancer, by comparing those
treated and not treated with PSK. They reported signiﬁ-
cantly (P\0.05) reduced frequency of analgesic use in
Table 8 RCTs of chemotherapy and/or radiotherapy with PSK for various cancers
References Tumor characteristics No. of patiens Treatment Results P value
5-year survival rates
Go [97] Nasopharyngeal carcinoma 17
17
A: RT(±CT
a) ? PSK
B: RT(±CT)
28%
15%
0.043
3-year DFS rates 4 groups
Matsumoto [98] Superﬁcial bladder tumor
pTa, pT1
G1, G2
65
67
65
66
A: Resection?PSK
B: Resection only
C: Resection?CQ?PSK
D: Resection?CQ
56.3%
32.6%
43.1%
35.6%
0.026
A versus B
0.008
A versus D
0.006
5-year survival rates
Ogoshi [99] Esophageal cancer
stage I–IV
38
31
56
49
A: Resection?RT?PSK
B: Resection?RT
C: Resection?RT?CT
b?PSK
D: Resection?RT?CT
42.3%
40.0%
37.2%
29.1%
C versus D
0.1930
10-year survival rates 3 groups
Iino [100] Breast cancer 74
76
77
A: Resection?FEMP
c?PSK
B: Resection?FEMP?Levamisole
C: Resection?FEMP
81.8%
76.9%
64.6%
0.1686
A versus C
0.0706
RT radiotherapy, CT chemotherapy, DFS disease-free survival, pT pathologic tumor, G grade, CQ carboquone
a Cisplatin or 5-FU or methotrexate or vincristine
b Bleomycin or pepleomycin?tegafur
c 5-FU?CPA?MMC?prednisolone
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123patients treated with PSK, which suggested that PSK had
some effect on cancer pain relief. Apart from its anticancer
effects, PSK is a useful agent in cancer treatment as shown
by the above studies.
Concluding remarks and future perspectives
Recent developments in the investigations of the mecha-
nisms of action of PSK and its main clinical effects have
been reviewed. Regarding the action of PSK against
immunosuppression, PSK has been reported to restore or
attenuate immunosuppression due to various factors. With
regard to the actions on immune cells, the induction of DC
maturation, the correction of Th1/Th2 imbalance, etc. have
been reported. Furthermore, the involvement of PSK in
intracellular signal transduction pathways also begins to
unfold. With regard to the direct action on tumors, con-
siderable knowledge about apoptosis induction by PSK has
been accumulating, and the anti-metastatic effect and
chemotherapy potentiating effect due to direct action on
tumors have been reported. Future studies of the actions of
PSK on immune cells and tumor cells at the molecular
level under various conditions, and identiﬁcation of the
target molecules of PSK, are necessary to clearly deﬁne the
whole mechanisms of action of PSK. Furthermore, it is
essential to investigate the actions of PSK along with
recent advances in molecular biology and tumor
immunology. Although many research results on the
mechanisms of action of PSK have been reported, it is
undeniable that the main mechanism of action is unclear. It
seems that PSK is an immunomodulator rather than a
purely immunopotentiator [106]. PSK probably does not
exert the same actions in all patients. The effects of PSK
under different local (tumor site) or systemic immune
conditions and tumor cell properties, and the mechanism of
action of PSK in each circumstance should be studied.
The beneﬁcial effect of PSK as postoperative adjuvant
therapy for gastric and colorectal cancer has been shown in
multiple RCTs. In addition, the effects of PSK in gastric
and colorectal cancer have been veriﬁed in multiple meta-
analyses. Prolongation of the remission period has also
been found in small-cell lung cancer. The combined effect
or comparison of combined formulation and biochemical
modulation of ﬂuoropyrimidine anticancer agents is being
examined by RCTs, and the results will be available in the
near future. Besides gastric, colorectal and small-cell lung
cancer, PSK also exhibits reasonable effects on other
cancers. These results are expected, because, unlike che-
motherapeutic agents, PSK exerts anticancer effects
through acting on host immunity. Also, PSK causes few
adverse reactions and has been reported to reduce those
associated with chemotherapy, improve QOL, and mitigate
cancer pain. The next step of PSK research is to deﬁne
which type of patient and disease conditions will allow
PSK to exert its optimal effect, irrespective of cancer type.
In this regard, there is an urgent need to elucidate the
mechanisms of action of PSK at the molecular level so as
to identify the biomarkers. Achievement of these goals will
beneﬁt patients from the personalized medicine point of
view.
Several reports have already suggested that the patient’s
immune function, as indicated by blood IAP level, periph-
eral granulocyte/lymphocyte ratio, and DC inﬁltration of
Table 9 Other effects of PSK in cancer therapy
References Evaluation Tumor
characteristics
No. of
patients
Treatment Results
Kohara
[102]
Toxicity of
chemotherapy
Solid tumors 20
49
A: 5-FU (dry syrup)
? PSK
B: 5-FU (dry syrup)
Frequency of chemotherapy toxicity
A: 7 cases (35.0%)
B: 26 cases (53.1%)
Sadahiro
[103]
Immune cells Rectal cancer 15
15
A: RT?S-1?PSK
(preoperative)
B: RT?S-1
(preoperative)
Increases of the proportion of NK cells in the
peripheral blood (P = 0.003) and cytotoxic T-cell
counts in the peri-tumoral and normal mucosa
(P=0.005, 0.003)
Yoshimura
[104]
QOL Stage III, IV
adenocarcinoma
of the lung,
inoperable
10
10
A:
CDDP?VDS?PSK
B: CDDP?VDS
Good score of QOL
A[B
Motai
[105]
Cancerous pain Nasopharyngeal
carcinoma
31
31
A: PSK
B: Non-PSK
Frequency of analgesic use
A: 72.9 ± 16.2
B: 146.9 ± 43.6
P\0.05
5-FU 5-ﬂuorouracil, RT radiation therapy, S-1 tegafur–gimeracil–oteracil potassium, CDDP cisplatin, VDS vindesine, QOL quality of life
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123Table 10 Potential biomarkers of PSK
Subjects Potential biomarker References
Human colon cancer cell line (in
vitro)
Expression of ECA39 protein in tumor cells Yoshikawa
[111]
Colon cancer patients Diffuse nuclear accumulation of b-catenin activation in primary tumor Yamashita
[112]
Colon cancer patients Preoperative peripheral blood CEA level: C3.0 ng/ml
Preoperative PPD skin reaction level:\19.0 nm
Takahashi
[113]
Colorectal cancer patients Increase of NK cell population in peripheral blood after PSK administration Ohwada [114]
Colorectal cancer patients Ratio of CD4
? IL-10
? T-cell percentage in peripheral blood before and after PSK
treatment:\0.8
Yoshino [46]
Gastric or colorectal cancer
patients
In vitro activation level of peripheral blood lymphocytes by PSK Yoshinaga
[116]
CEA carcinoembryonic antigen, PPD puriﬁed protein derivative of tuberculin, NK natural killer
Fig. 8 PSK-stimulated activation of blood lymphocytes in healthy
volunteers and cancer patients (a). Effects of adjuvant immunoche-
motherapy with PSK on 10-year OS in gastric cancer (b) and
colorectal cancer (c) patients with low or high PSK-induced
lymphocyte activation level. The increase in DNA synthesis of
lymphocytes was deﬁned as ratio of the level of PSK-treated
lymphocytes versus PSK-non-treated lymphocytes. Asterisk adjusted
by gender, age, Dukes’ stage, tumor size, lymphatic vessel invasion,
and venous invasion. Adapted from Sugimachi et al. [115] and
Yoshinaga et al. [116]
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123tumor tissue, as well as HLA type, is a potential biomarker
of response to PSK therapy [107–110]. The recent advances
in biomarker research are summarized in Table 10.
Yoshikawa et al. [111] have examined the action of PSK on
human colorectal cancer cell line, using protein microarray
with antibodies against 500 human proteins and found that
expression of ECA39 protein was reduced. ECA39
expression in resected tumors is associated with poor
DFS and OS; therefore, these ﬁndings suggest that ECA
expression is a marker of response to PSK therapy.
Yamashita et al. [112] have examined nuclear translocation
of b-catenin in cancer tissues of colorectal cancer patients
and reported that OS was improved with PSK immun-
ochemotherapy in patients showing diffuse b-catenin
nuclear accumulation in tumor tissues. Takahashi et al.
[113] have reported that, in colon cancer patients with
preoperative peripheral blood carcinoembryonic antigen
level: C3.0 ng/ml or PPD skin reaction level: \19.0 mm,
7-year DFS and OS were signiﬁcantly better with postop-
erative adjuvant immunochemotherapy using PSK than in
patients treated with chemotherapy alone. Ohwada et al.
[114] have reported that colorectal cancer patients with an
increase in NK cell population at 3 months after surgery
had more favorable DFS when treated with PSK immun-
ochemotherapy than chemotherapy alone. Yoshino et al.
[46] have found that relapse (3 years) did not occur in
colorectal cancer patients with peripheral blood CD4
?
IL-10
? T-cell ratios (post-/pre-PSK treatment):\0.8 when
PSK was administered 1 week before surgery, and reported
that these patients might be candidate PSK responders. We
have examined the outcome in gastric and colorectal cancer
patients using the PSK-induced peripheral blood lympho-
cyte blastogenesis reaction as an indicator for response to
PSK therapy and gained an impression that patients
with high reactivity had better survival outcome (Fig. 8)
[115, 116]. We have also investigated the in vitro effect of
PSK on PBMC gene expression in healthy individuals using
DNA microarray analysis and observed changes in
expression of six genes in four of ﬁve individuals. Using
real-time RT-PCR, we found increased expression of
IL-18BP, CCL2, IL-8, and vesicle amine transport 1
homolog and reduced expression of chondroitin sulfate
proteoglycan in all ﬁve individuals [117]. The relationship
between expression of these genes and relapse suppres-
sion needs to be examined further. We speculate that
more than one biomarker might indicate response to PSK
therapy. Identiﬁcation of these biomarkers one by one
will pave the way for the future use of PSK in cancer
treatment.
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